Harrow Health Stock Performance
| HROW Stock | USD 42.06 0.84 1.96% |
Harrow Health has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.98, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Harrow Health will likely underperform. Harrow Health right now retains a risk of 4.21%. Please check out Harrow Health potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Harrow Health will be following its current trending patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Harrow Health are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Harrow Health is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return (4.88) | Five Day Return 1.94 | Year To Date Return 241.48 | Ten Year Return 403.17 | All Time Return (65.99) |
Last Split Factor 1:5 | Last Split Date 2013-02-08 |
1 | Disposition of 150000 shares by Baum Mark L of Harrow Health subject to Rule 16b-3 | 08/30/2024 |
2 | Harrow Health Unveils Performance Strategy to Investors - TipRanks | 09/09/2024 |
3 | Disposition of 90000 shares by Saharek John P. of Harrow Health at 7.37 subject to Rule 16b-3 | 09/11/2024 |
4 | Acquisition by Opaleye Management Inc. of 10000 shares of Harrow Health at 6.7632 subject to Rule 16b-3 | 09/13/2024 |
5 | Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in ... | 10/10/2024 |
6 | Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024 | 10/31/2024 |
7 | Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrows Branded Eyecare Products | 11/07/2024 |
8 | Harrow is on the Move, Heres Why the Trend Could be Sustainable | 11/08/2024 |
9 | Cisco, Cyberark, Suncor to report earnings Wednesday | 11/12/2024 |
10 | Harrow Inc Q3 2024 Earnings Report Preview What To Look For | 11/13/2024 |
11 | Harrow Inc Q3 2024 Earnings Revenue at 49.3M, Misses Estimate EPS Loss of 0. ... | 11/14/2024 |
12 | Harrow Inc Q3 2024 Earnings Call Highlights Record Revenue and Strategic Growth Amid ... | 11/15/2024 |
13 | Harrows ImprimisRx Subsidiary Receives 34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. | 11/21/2024 |
14 | OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case | 11/22/2024 |
| Begin Period Cash Flow | 96.3 M |
Harrow |
Harrow Health Relative Risk vs. Return Landscape
If you would invest 4,340 in Harrow Health on August 27, 2024 and sell it today you would lose (50.00) from holding Harrow Health or give up 1.15% of portfolio value over 90 days. Harrow Health is currently generating 0.0722% in daily expected returns and assumes 4.2062% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Harrow, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Harrow Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Harrow Health's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Harrow Health, and traders can use it to determine the average amount a Harrow Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0172
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | HROW | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.21 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Harrow Health is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Harrow Health by adding it to a well-diversified portfolio.
Harrow Health Fundamentals Growth
Harrow Stock prices reflect investors' perceptions of the future prospects and financial health of Harrow Health, and Harrow Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Harrow Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.0168 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.65 B | ||||
| Shares Outstanding | 35.61 M | ||||
| Price To Earning | 24.45 X | ||||
| Price To Book | 26.35 X | ||||
| Price To Sales | 9.03 X | ||||
| Revenue | 130.19 M | ||||
| Gross Profit | 63.21 M | ||||
| EBITDA | 9.72 M | ||||
| Net Income | (24.41 M) | ||||
| Cash And Equivalents | 51.7 M | ||||
| Cash Per Share | 1.91 X | ||||
| Total Debt | 190.5 M | ||||
| Current Ratio | 5.01 X | ||||
| Book Value Per Share | 1.64 X | ||||
| Cash Flow From Operations | 3.84 M | ||||
| Earnings Per Share | (0.95) X | ||||
| Market Capitalization | 1.53 B | ||||
| Total Asset | 311.75 M | ||||
| Retained Earnings | (133.9 M) | ||||
| Working Capital | 90.14 M | ||||
| Current Asset | 8.77 M | ||||
| Current Liabilities | 2.56 M | ||||
About Harrow Health Performance
Evaluating Harrow Health's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Harrow Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Harrow Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 100.06 | 92.81 | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Assets | (0.08) | (0.08) | |
| Return On Equity | (0.35) | (0.36) |
Things to note about Harrow Health performance evaluation
Checking the ongoing alerts about Harrow Health for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Harrow Health help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Harrow Health had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 130.19 M. Net Loss for the year was (24.41 M) with profit before overhead, payroll, taxes, and interest of 63.21 M. | |
| Harrow Health has a frail financial position based on the latest SEC disclosures | |
| About 59.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case |
- Analyzing Harrow Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Harrow Health's stock is overvalued or undervalued compared to its peers.
- Examining Harrow Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Harrow Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Harrow Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Harrow Health's stock. These opinions can provide insight into Harrow Health's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Harrow Stock Analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.